Bioprocess Bags Market Seen Soaring ~17.5% Growth to Reach USD Billion by 2032, Projects UnivDatos

According to a new report by UnivDatos, The Bioprocess Bags Market was valued at approximately USD 3.85 Billion in 2023 and is expected to grow at a substantial CAGR of around 17.5% during the forecast period (2024-2032). The growth of the bioprocess bags market reflects the global trend towards the usage of single-use technologies in biopharmaceutical production. These industries avail themselves by minimized lead time, decreased probability of contamination, and improved production. The bioprocess bags market expansion is fueled by the increasing need for biologics, biosimilars, and vaccines. In October 2022, Austrian solution provider Single Use Support GmbH expanded its product portfolio with new single-use bioprocess containers under the brand name IRIS. The pioneering company leverages its know-how to provide reliable process solutions in the field of biopharmaceutical fluid management, continuing to pursue its vendor-agnostic approach.

Segments that transform the industry

• Based on product type, the market is segmented into single-use bioprocessing bags and multi-use bioprocessing bags. Single-use bioprocessing bags held a significant share of the market in 2023 owing to enhanced growth by facilitating rapid production scaling, the need to clean them less often, and possessing lower risk of cross-contamination. Adding to this, companies use these bags in bioprocessing due to their adaptability to bioprocesses such as media preparation, mixing, and product storage. Their adaptability to automated bioreactors and closed systems makes them fundamental to the current biomanufacturing industry. For instance, on March 28, 2022 — ILC Dover LP (“ILC Dover” or the “Company”), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products for handling and supply of sterile liquids for the biotherapeutics market. This expansion is a continuation of ILC Dover’s solution set across the entire biotherapeutic and pharmaceutical manufacturing workflow, from powder containment and handling, through sterile liquid handling and pre-filled liquid and powder bags.

According to the report, the impact of Bioprocess Bags has been identified to be high for the Asia-Pacific area. Some of how this impact has been felt include:

Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to the booming biotechnology industry and rapidly growing consumption of biopharma products in the region’s emerging giants such as China and India. It is one of the most important bioprocessing locations because government policies support the production of local goods along with cheaper manufacturing expenses. Increased spending on single-use technologies and increasing outsourcing of CMC services through more CMOs/CROs are critical drivers. There are several reasons companies opt for bioprocess bags compliance with international quality standards and the need to scale up biosimilars and vaccine production. The region’s emphasis on new technologies and export-oriented biomanufacturing also drives adoption even more.

On June 1, 2021, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that it has acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2024−2032.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis By Type, By Product Type, By Workflow, By End User, By Region/Country

Competitive Landscape – Top Key Vendors and Other Prominent Vendors